Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
| Conditionnement | Référence | Disponibilité | Prix |
|---|---|---|---|
| 5 mg | Vérifier la disponibilité des articles du panier | 102,00 € 86,70 € | |
| 25 mg | Vérifier la disponibilité des articles du panier | 414,00 € 351,90 € |
A propos de cet article
Formule empirique (notation de Hill) :
C30H35NO3
Numéro CAS:
Poids moléculaire :
457.60
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥95% (HPLC)
Form:
film or powder (or oil)
86,70 €
Tarif102,00 ۃconomiser 15 %Promotion Internet uniquement
Vérifier la disponibilité des articles du panier
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Ormeloxifene, ≥95% (HPLC)
assay
≥95% (HPLC)
form
film or powder (or oil)
color
colorless to yellow-white
storage temp.
2-8°C
SMILES string
CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5
InChI
1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
InChI key
XZEUAXYWNKYKPL-WDYNHAJCSA-N
Biochem/physiol Actions
Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.
non-steroidal selective estrogen receptor modulator (SERM)
1 of 1
Cet article | |||
|---|---|---|---|
| assay ≥95% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| form film or powder (or oil) | form powder | form powder | form powder |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| color colorless to yellow-white | color - | color - | color white to beige |
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
William R Surin et al.
Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)
Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases
Bilal Bin Hafeez et al.
Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)
Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism
Geetika Kharkwal et al.
Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)
Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| SML2237-5MG | 04061835494774 |
| SML2237-25MG | 04061835494767 |



